Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening
-- Population Genetics Sequencing Panel Incorporates Global Genetic Variations for Superior Study of Disease and Target Discovery --
Genome-wide association studies using genotyping microarrays have long been a critical tool in understanding how genetic variation impacts disease. Recent reports highlight that the majority of genetic association studies completed with commercially available microarray platforms include genetic markers from people of European descent predominantly, with little global diversity. Underrepresentation of diverse populations in genomic analysis hinders the ability to fully understand disease cause and correlation and perpetuates inequality in patient care.
Addressing this gap, the Twist Diversity SNP panel is inclusive of approximately 1.4 million globally-representative genetic variations known as single-nucleotide polymorphisms (SNPs). Under its new agreement with the RGC, Twist will make this product broadly available to customers beginning today.
“Leveraging Twist’s custom NGS panel design capabilities, the RGC developed a first-of-its-kind, proprietary population genotyping assay that includes DNA probes that capture globally diverse genetic sequence variations,” said
“While SNP microarray has been the gold standard of genetic study, we have more and more customers asking for a complete genotyping solution that allows flexibility for customized disease research and we believe this is the future of disease marker testing,” said Emily M. Leproust, Ph.D., CEO and co-founder of
The Diversity SNP assay also enables research centers to consolidate their data generation costs and physical footprints by leveraging next-generation sequencers for both genotyping and exome/custom panels rather than maintaining separate genotyping instrumentation and lab space. While microarrays provide information about the presence or absence of a genetic variant, the Diversity SNP panel produces dynamic, multi-faceted information across a broad spectrum of the population. In addition, the panel can be iterated quickly to build a customized assay incorporating real-time journal and database entries.
As the first release in Twist’s emerging Targeted Genotyping-By-Sequencing (GBS) portfolio, the Twist Diversity SNP panel leverages Twist’s best-in-class DNA synthesis platform to generate a global panel of more than 600,000 probes governing approximately 1.4 million SNPs. Used separately as a stand-alone genotyping panel or as an addition (spike-in) into Twist’s Human Comprehensive Exome panel, this assay gives researchers a new ethnicity-neutral gold standard to use in generating genotyping data to match with their sequencing and other genomic data. Compared to historical microarray platforms that offer fixed content updated occasionally, the Twist Diversity SNP panel allows scientists the freedom to choose between standardized catalogue content or - with Twist’s custom NGS probes capabilities - the ability to build upon this foundation with additional regions of interest, creating unique content for any focused disease research application. For higher throughput users, this approach also enables improved scale-up economics with no requirement for additional capital investment.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation Twist’s ability to make the Twist Diversity SNP panel broadly available to customers in Spring 2021, the Twist Diversity SNP panel’s ability to help data centers consolidate their data generation costs and physical footprints, ability to be iterated quickly and role in future of disease marker testing, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products
SVP, Corporate Affairs